Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna (MRNA) remains at the forefront of mRNA technology innovation, developing transformative therapies for infectious diseases, oncology, and rare conditions. This dedicated news hub provides investors and healthcare professionals with essential updates directly from the company and verified sources.
Access official press releases covering clinical trial results, regulatory milestones, and strategic partnerships, alongside analysis of quarterly earnings and pipeline developments. Our curated collection ensures you stay informed about Moderna's progress in advancing mRNA-based medicines without promotional bias.
Key updates include developments in respiratory vaccines, cancer immunotherapy candidates, and rare disease treatments. Bookmark this page for real-time access to Moderna's verified announcements and objective reporting on one of biotechnology's most innovative platforms.
Moderna (Nasdaq: MRNA) announces new data confirming that its COVID-19 vaccine candidate, mRNA-1273, remains stable at 2° to 8°C for 30 days, extending previous estimates from 7 days. The vaccine can also be stored at -20°C for up to six months and room temperature for 12 hours. These stability improvements are crucial for distribution across pharmacies and hospitals, facilitating wider vaccinations. Moderna is working with regulatory bodies to submit this data for approval while ensuring vaccine accessibility and streamlined logistics.
Moderna (Nasdaq: MRNA) announced that Swissmedic has initiated a rolling review of its COVID-19 vaccine candidate, mRNA-1273. This follows positive results from a preclinical study and interim analysis of Phase 1 trials showing strong immune responses. The rolling review allows for quicker authorization, contingent on meeting Swissmedic's safety and efficacy standards. Moderna completed enrollment for its Phase 3 COVE study with 30,000 participants, focusing on the vaccine's effectiveness across age groups. CEO Stéphane Bancel expressed optimism about the collaboration with Swissmedic, highlighting promising data.
Moderna, Inc. (Nasdaq: MRNA) announced the completion of case accrual for the first interim analysis of its Phase 3 COVE study of mRNA-1273, a COVID-19 vaccine candidate. With significantly increased case identification, the analysis will include more than the targeted 53 cases. The COVE study enrolled 30,000 participants, focusing on those at high risk for severe COVID-19. The study aims to prevent symptomatic and severe disease, with results expected to influence regulatory decisions.
Moderna, Inc. (Nasdaq: MRNA) has released interim data from its Phase 1 study of the mRNA personalized cancer vaccine (PCV) mRNA-4157, presented at SITC 2020. The study involved 10 HPV(-) Head and Neck Squamous Cell Carcinoma patients and 17 Micro-Satellite Stable Colorectal Cancer patients. Notably, 50% of patients in the HPV(-) cohort experienced tumor shrinkage, with two achieving complete responses. The overall disease control rate was 90%, and median progression-free survival reached 9.8 months. Moderna plans to expand the cohort based on this encouraging data.
Moderna (Nasdaq: MRNA) announced its participation in two upcoming investor conferences. The Credit Suisse 29th Annual Virtual Healthcare Conference will take place on November 11, 2020, at 8:00 a.m. ET, followed by the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 11:25 a.m. ET. Live webcasts of these presentations will be accessible on Moderna's website under the 'Events and Presentations' section, with replays available for 30 days following each event.
Moderna (Nasdaq: MRNA) has confirmed an agreement with Japan's Ministry of Health and Takeda Pharmaceutical to supply 50 million doses of its COVID-19 vaccine candidate, mRNA-1273. This partnership aims to ensure rapid distribution of the vaccine in Japan, pending regulatory approvals. Moderna will handle manufacturing and supply, while Takeda, supported by Japanese authorities, will oversee import and distribution efforts. CEO Stéphane Bancel expressed gratitude to Japanese partners, highlighting the confidence in mRNA-1273 amid promising clinical data.
Moderna, Inc. (Nasdaq: MRNA) announced a supply agreement with Qatar's Ministry of Public Health for its COVID-19 vaccine candidate, mRNA-1273, aiming to enhance access to vaccines in Qatar. The Phase 3 COVE study is fully enrolled with 30,000 participants, demonstrating strong immune responses in interim analyses. Moderna plans to manufacture 500 million to 1 billion doses annually starting in 2021. This development underscores Moderna's commitment to combating the pandemic, leveraging its innovative mRNA technology.
Moderna, Inc. (Nasdaq: MRNA) has completed enrollment of 30,000 participants for its Phase 3 COVE study of mRNA-1273, a COVID-19 vaccine candidate. Over 25,650 participants have received their second dose. The company is collaborating with NIAID and BARDA, prioritizing groups at high risk for severe COVID-19, including 7,000 individuals over 65. Enrollment also included over 11,000 participants from diverse communities, representing 37% of the population. The next steps involve analyzing safety data and determining emergency use authorization based on the potential benefits and risks.
Moderna, Inc. (Nasdaq: MRNA) announced a live conference call on October 29, 2020, at 8:00 a.m. ET to present its third quarter 2020 financial results and provide a corporate update. Interested participants can join via phone or access a webcast from Moderna's Investor Relations website. The call will also feature insights into Moderna's advancements in mRNA technology, focusing on therapeutics and vaccines for various diseases. The archived audio of the call will be available for one year post-event.
FAQ
What is the current stock price of Moderna (MRNA)?
What is the market cap of Moderna (MRNA)?
